Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells
Liu Y, Pan Y, Hu Z, Wu M, Wang C, Feng Z, Mao C, Tan Y, +8 more
Clinical Infectious Diseases (2020) · n=76
In 76 severe COVID-19 patients across two Wuhan hospitals, thymosin α-1 reduced 28-day mortality from 30.0% to 11.1% — restored CD8+ and CD4+ T-cell counts and reduced PD-1/Tim-3 exhaustion markers, with the largest mortality benefit in patients with the deepest lymphopenia at baseline.
This 2020 Clinical Infectious Diseases paper is the most-cited COVID-19 evidence in the thymosin α-1 literature and the cornerstone reference for the molecule's emergency-use deployment across hospitalised COVID-19 patients in mainland China during the first pandemic wave. The investigators conducted a retrospective cohort analysis of 76 severely ill COVID-19 patients admitted to two Wuhan hospitals between December 2019 and March 2020. The thymosin α-1-treated arm showed 28-day mortality of 11.1% versus 30.0% in untreated controls (p = 0.044). The mortality benefit was concentrated in the lymphopenic subgroups: patients with CD8+ T cells below 400/μL or CD4+ T cells below 650/μL at baseline derived the most pronounced benefit. Mechanistically, thymosin α-1 treatment restored CD8+ and CD4+ T-cell numbers in circulation, reduced T-cell-exhaustion markers PD-1 and Tim-3 on CD8+ cells, and increased TREC-measured thymic output — consistent with the proposed mechanism of action of the molecule (immune reconstitution and reversal of activation-induced T-cell exhaustion) in a clinical setting where that pathology was acute and quantifiable. The paper drove subsequent inclusion of thymosin α-1 in Chinese national COVID-19 management guidelines and motivated several follow-up cohort studies and meta-analyses.
This is a retrospective cohort study, not a randomized controlled trial — treatment-group assignment was clinician-determined, not random, and despite multivariable adjustment, residual confounding by indication is plausible. The Wuhan first-wave context featured rapidly evolving supportive-care protocols, ICU bed availability constraints, and patient-mix variability that retrospective design cannot fully capture. The 76-patient sample is small for a mortality endpoint with wide confidence intervals around the 11.1% vs 30.0% comparison; the p = 0.044 statistic is at the conventional significance threshold rather than well clear of it. Subsequent COVID-19 thymosin α-1 trials have been mixed; a 2023 systematic review and meta-analysis (Inflammopharmacology) found mortality benefit in pooled cohort data but inconsistent results when restricted to randomized trials. The post-Omicron pandemic context, with widespread vaccination and changed disease severity, has substantially altered the population to which findings of this magnitude would generalise. Read the paper as the foundational COVID-19 evidence base for the molecule, not as definitive randomized-trial proof of efficacy.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.